CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Twist Bioscience Corporation - TWST CFD

38.16
1.6%
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.21
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Twist Bioscience Corp ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 38.78
Open* 38.38
1-Year Change* 97.63%
Day's Range* 36.4 - 38.38
52 wk Range 11.46-39.74
Average Volume (10 days) 1.06M
Average Volume (3 months) 25.88M
Market Cap 1.96B
P/E Ratio -100.00K
Shares Outstanding 57.78M
Revenue 245.11M
EPS -3.60
Dividend (Yield %) N/A
Beta 1.61
Next Earnings Date Feb 2, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 4, 2024 38.16 -0.84 -2.15% 39.00 39.00 36.25
Mar 1, 2024 38.78 -0.54 -1.37% 39.32 40.59 37.68
Feb 29, 2024 39.08 -2.45 -5.90% 41.53 41.92 39.04
Feb 28, 2024 39.96 1.10 2.83% 38.86 41.50 38.86
Feb 27, 2024 40.90 0.00 0.00% 40.90 41.77 40.54
Feb 26, 2024 40.50 2.93 7.80% 37.57 40.60 37.12
Feb 23, 2024 37.94 -0.02 -0.05% 37.96 38.53 37.47
Feb 22, 2024 38.52 -0.03 -0.08% 38.55 38.93 37.70
Feb 21, 2024 38.22 0.21 0.55% 38.01 38.56 36.68
Feb 20, 2024 39.41 -0.10 -0.25% 39.51 40.64 38.48
Feb 16, 2024 40.78 0.80 2.00% 39.98 42.31 39.33
Feb 15, 2024 41.43 1.11 2.75% 40.32 42.99 39.55
Feb 14, 2024 39.78 1.98 5.24% 37.80 40.32 36.54
Feb 13, 2024 36.94 0.55 1.51% 36.39 38.02 35.12
Feb 12, 2024 40.53 2.97 7.91% 37.56 40.76 37.22
Feb 9, 2024 38.08 1.74 4.79% 36.34 38.27 36.15
Feb 8, 2024 36.41 1.78 5.14% 34.63 36.98 34.31
Feb 7, 2024 34.85 -1.35 -3.73% 36.20 36.20 34.68
Feb 6, 2024 36.91 1.71 4.86% 35.20 37.29 35.20
Feb 5, 2024 36.16 1.11 3.17% 35.05 36.37 33.93

Twist Bioscience Corporation Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

16:10

Country

US

Event

Twist Bioscience Corp at TD Cowen Health Care Conference
Twist Bioscience Corp at TD Cowen Health Care Conference

Forecast

-

Previous

-
Friday, May 3, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 Twist Bioscience Corp Earnings Release
Q2 2024 Twist Bioscience Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 203.565 132.333 90.1 54.385 25.427
Revenue 203.565 132.333 90.1 54.385 25.427
Cost of Revenue, Total 119.33 80.62 61.406 47.426 32.189
Gross Profit 84.235 51.713 28.694 6.959 -6.762
Total Operating Expense 433.734 285.059 230.179 163.235 95.986
Selling/General/Admin. Expenses, Total 212.949 135.901 103.267 80.126 43.45
Research & Development 120.307 69.072 43.006 35.683 20.347
Operating Income -230.169 -152.726 -140.079 -108.85 -70.559
Interest Income (Expense), Net Non-Operating 2.982 0.068 0.712 1.738 -0.314
Other, Net -1.087 -1.37 -0.182 -0.265 -0.121
Net Income Before Taxes -228.274 -154.028 -139.549 -107.377 -70.994
Net Income After Taxes -217.863 -152.098 -139.931 -107.669 -71.236
Net Income Before Extra. Items -217.863 -152.098 -139.931 -107.669 -71.236
Net Income -217.863 -152.098 -139.931 -107.669 -71.236
Income Available to Common Excl. Extra. Items -217.863 -152.098 -139.931 -107.669 -71.236
Income Available to Common Incl. Extra. Items -217.863 -152.098 -139.931 -107.669 -71.236
Diluted Net Income -217.863 -152.098 -139.931 -107.669 -71.236
Diluted Weighted Average Shares 53.885 48.251 39.19 27.4618 26.61
Diluted EPS Excluding Extraordinary Items -4.04311 -3.15222 -3.57058 -3.92068 -2.67704
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -4.27052 -3.15942 -3.1974 -3.92068 -2.67704
Unusual Expense (Income) -18.852 -0.534 22.5
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 63.74 60.18 54.243 57.306 56.113
Revenue 63.74 60.18 54.243 57.306 56.113
Cost of Revenue, Total 41.845 41.669 29.442 31.586 30.974
Gross Profit 21.895 18.511 24.801 25.72 25.139
Total Operating Expense 124.521 121.817 98.873 109.57 117.276
Selling/General/Admin. Expenses, Total 46.057 53.965 42.324 54.159 53.693
Research & Development 24.528 27.379 31.242 29.606 36.84
Unusual Expense (Income) 12.091 -1.196 -4.135 -5.781 -4.231
Operating Income -60.781 -61.637 -44.63 -52.264 -61.163
Interest Income (Expense), Net Non-Operating 3.967 3.462 3.039 1.902 0.722
Other, Net 0.041 -0.305 -0.157 -0.461 -0.225
Net Income Before Taxes -56.773 -58.48 -41.748 -50.823 -60.666
Net Income After Taxes -57.395 -59.156 -41.824 -51.115 -60.517
Net Income Before Extra. Items -57.395 -59.156 -41.824 -51.115 -60.517
Net Income -57.395 -59.156 -41.824 -51.115 -60.517
Income Available to Common Excl. Extra. Items -57.395 -59.156 -41.824 -51.115 -60.517
Income Available to Common Incl. Extra. Items -57.395 -59.156 -41.824 -51.115 -60.517
Diluted Net Income -57.395 -59.156 -41.824 -51.115 -60.517
Diluted Weighted Average Shares 57.041 56.777 56.444 56.525 56.287
Diluted EPS Excluding Extraordinary Items -1.00621 -1.0419 -0.74098 -0.90429 -1.07515
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.86843 -1.05559 -0.7886 -0.97077 -1.12401
Interest Expense (Income) - Net Operating
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 424.256 596.483 546.495 334.87 160.135
Cash and Short Term Investments 336.413 504.968 477.863 290.002 138.107
Cash & Equivalents 286.47 378.687 465.829 93.667 46.735
Short Term Investments 49.943 126.281 12.034 196.335 91.372
Total Receivables, Net 44.064 40.294 28.549 26.376 12.104
Accounts Receivable - Trade, Net 44.064 35.472 26.212 25.425 10.791
Total Inventory 32.063 39.307 31.8 12.289 7.33
Prepaid Expenses 11.716 11.914 8.283 6.203 2.51
Total Assets 776.403 961.378 702.097 398.882 186.994
Property/Plant/Equipment, Total - Net 203.361 214.389 105.702 59.165 20.835
Property/Plant/Equipment, Total - Gross 254.017 246.166 141.124 88.643 43.828
Accumulated Depreciation, Total -50.656 -31.777 -35.422 -29.478 -22.993
Goodwill, Net 85.811 85.811 22.434 1.138 1.138
Intangibles, Net 54.483 59.738 18.262 0.307 0.508
Other Long Term Assets, Total 8.492 4.957 9.204 3.402 4.378
Total Current Liabilities 73.323 90.663 63.052 36.029 30.354
Accounts Payable 14.052 20.092 14.9 4.83 9.76
Accrued Expenses 51.468 50.834 36.977 25.255 16.444
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 1.552 3.333 3.333
Other Current Liabilities, Total 7.803 19.737 9.623 2.611 0.817
Total Liabilities 152.971 171.993 121.276 62.62 34.912
Total Long Term Debt 0 0 0 1.403 4.4
Long Term Debt 0 1.403 4.4
Other Liabilities, Total 79.648 81.33 58.224 25.188 0.158
Total Equity 623.432 789.385 580.821 336.262 152.082
Common Stock 0.00058 0 0 0
Additional Paid-In Capital 1657.22 1619.64 1190.83 794.63 470.425
Retained Earnings (Accumulated Deficit) -1033.03 -828.416 -610.553 -458.455 -318.524
Other Equity, Total -0.75658 -1.843 0.546 0.087 0.181
Total Liabilities & Shareholders’ Equity 776.403 961.378 702.097 398.882 186.994
Total Common Shares Outstanding 57.557 56.523 49.499 45.083 32.8727
Other Current Assets, Total 0.084
Preferred Stock - Non Redeemable, Net 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 424.256 445.537 489.271 541.859 596.483
Cash and Short Term Investments 336.413 357.145 387.658 438.71 504.968
Cash & Equivalents 286.47 307.459 315.196 316.681 378.687
Short Term Investments 49.943 49.686 72.462 122.029 126.281
Total Receivables, Net 44.064 42.58 48.187 44.437 40.294
Accounts Receivable - Trade, Net 44.064 37.011 42.873 39.183 35.472
Total Inventory 32.063 36.354 39.923 44.597 39.307
Prepaid Expenses 11.716 9.458 13.503 14.115 11.914
Total Assets 776.403 810.332 853.924 909.97 961.378
Property/Plant/Equipment, Total - Net 203.361 212.806 217.208 218.607 214.389
Goodwill, Net 85.811 85.811 85.811 85.811 85.811
Intangibles, Net 54.483 55.775 57.068 58.361 59.738
Other Long Term Assets, Total 8.492 10.403 4.566 5.332 4.957
Total Current Liabilities 73.323 72.822 72.108 83.837 90.663
Accounts Payable 14.052 12.184 13.236 20.113 20.092
Accrued Expenses 51.468 50.727 48.832 47.902 50.834
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0 0
Other Current Liabilities, Total 7.803 9.911 10.04 15.822 19.737
Total Liabilities 152.971 152.782 149.992 163.645 171.993
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 79.648 79.96 77.884 79.808 81.33
Total Equity 623.432 657.55 703.932 746.325 789.385
Common Stock 0.00058 0.00057 0.00057 0.00057 0
Additional Paid-In Capital 1657.22 1644.98 1633.22 1617.17 1619.64
Retained Earnings (Accumulated Deficit) -1033.03 -986.791 -929.396 -870.24 -828.416
Other Equity, Total -0.75658 -0.63557 0.11043 -0.60957 -1.843
Total Liabilities & Shareholders’ Equity 776.403 810.332 853.924 909.97 961.378
Total Common Shares Outstanding 57.557 57.367 57.105 56.645 56.523
Long Term Investments
Property/Plant/Equipment, Total - Gross 254.017 258.465 258.581 254.296
Accumulated Depreciation, Total -50.656 -45.659 -41.373 -35.689
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -217.863 -152.098 -139.931 -107.669 -71.236
Cash From Operating Activities -124.385 -112.244 -142.255 -87.937 -66.164
Cash From Operating Activities 16.514 9.75 6.677 6.111 5.727
Non-Cash Items 82.32 39.485 16.175 10.625 3.565
Cash Taxes Paid 0.246 0.101 0.172 0.291 0.179
Cash Interest Paid 0.009 0.167 0.438 0.779 0.751
Changes in Working Capital -5.356 -9.381 -25.176 2.996 -4.22
Cash From Investing Activities -232.93 156.155 -114.65 -104.81 27.306
Capital Expenditures -101.857 -27.061 -9.868 -14.757 -3.688
Other Investing Cash Flow Items, Total -131.073 183.216 -104.782 -90.053 30.994
Cash From Financing Activities 270.534 329.182 303.732 158.578 88.822
Issuance (Retirement) of Stock, Net 272.092 332.515 307.065 161.078 91.181
Issuance (Retirement) of Debt, Net -1.558 -3.333 -3.333 -2.5 0
Net Change in Cash -87.1 373.113 46.848 -34.139 49.964
Financing Cash Flow Items 0 0 -2.359
Foreign Exchange Effects -0.319 0.02 0.021 0.03 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -100.98 -41.824 -217.863 -166.748 -106.231
Cash From Operating Activities -98.358 -54.07 -124.385 -123.118 -88.993
Cash From Operating Activities 12.32 5.292 16.514 11.562 7.118
Non-Cash Items 3.767 -5.919 82.32 51.126 34.029
Cash Taxes Paid 0.137 0.052 0.246 0.13 0.13
Cash Interest Paid 0 0 0.009 0.009 0.009
Changes in Working Capital -13.465 -11.619 -5.356 -7.881 -12.864
Cash From Investing Activities 34.189 -6.971 -232.93 -235.713 -239.876
Capital Expenditures -20.877 -11.824 -101.857 -85.395 -44.753
Other Investing Cash Flow Items, Total 55.066 4.853 -131.073 -150.318 -195.123
Cash From Financing Activities 1.13 -0.395 270.534 269.294 270.605
Issuance (Retirement) of Stock, Net 1.13 -0.395 272.092 270.852 272.163
Issuance (Retirement) of Debt, Net 0 0 -1.558 -1.558 -1.558
Foreign Exchange Effects 0.341 0.268 -0.319 -0.001 0.104
Net Change in Cash -62.698 -61.168 -87.1 -89.538 -58.16
Deferred Taxes 0 0 -11.177 -11.045
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
ARK Investment Management LLC Investment Advisor 11.8231 6785983 -173257 2023-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 10.2329 5873298 185038 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 8.6361 4956788 368466 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 8.4458 4847576 -428265 2023-06-30 LOW
William Blair Investment Management, LLC Investment Advisor/Hedge Fund 6.2997 3615798 1561277 2023-06-30 LOW
Nikko Asset Management Co., Ltd. Investment Advisor/Hedge Fund 6.07 3483932 -82307 2023-09-30 LOW
Millennium Management LLC Hedge Fund 5.3068 3045913 548499 2023-09-01 HIGH
JP Morgan Asset Management Investment Advisor 4.7332 2716650 439754 2023-06-30 LOW
JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 3.9526 2268659 603622 2023-06-30 LOW
Artisan Partners Limited Partnership Investment Advisor 3.1677 1818153 1473632 2023-06-30 LOW
Citadel Advisors LLC Hedge Fund 2.7262 1564727 390899 2023-06-30 LOW
Credit Suisse Funds AG Investment Advisor/Hedge Fund 2.5085 1439787 16075 2023-06-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 2.2582 1296107 190102 2023-06-30 LOW
Baillie Gifford & Co. Investment Advisor 2.2126 1269926 189896 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.0482 1175592 68584 2023-06-30 LOW
Marshall Wace LLP Investment Advisor/Hedge Fund 1.5706 901464 541327 2023-06-30 HIGH
Tao Capital Management LP Investment Advisor 1.444 828815 0 2023-06-30 LOW
Fisher Investments Investment Advisor/Hedge Fund 1.3685 785457 8081 2023-06-30 LOW
Mellon Investments Corporation Investment Advisor/Hedge Fund 1.3529 776511 -36040 2023-09-30 LOW
Morgan Stanley & Co. LLC Research Firm 1.182 678440 206621 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Twist Bioscience Corporation Company profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company''s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreement with ImmunoPrecise Antibodies Ltd. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Industry: Biopharmaceuticals

681 Gateway Blvd.
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

BTC/USD

66,990.40 Price
-0.700% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

78.22 Price
-0.320% 1D Chg, %
Long position overnight fee 0.0260%
Short position overnight fee -0.0479%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

2,116.37 Price
+0.070% 1D Chg, %
Long position overnight fee -0.0189%
Short position overnight fee 0.0107%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

18,171.90 Price
-0.210% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading